From beef stew to biologics
Oregon Freeze Dry is expanding its operations in the biopharmaceutical sphere, aiming to take a bite out of a $400 billion global market that includes vaccines and biotherapeutics. Last fall, the company opened a state-of-the-art $7.5 million development and clinical supply facility at its headquarters in Albany.
The facility is on track to receive Biosafety Level 2 certification from the Food and Drug Administration in October. Once up and running, it will be able to produce supplies of biologics for clinical trials and for small-scale commercial production.